大B细胞淋巴瘤-话题@MedSci

#大B细胞淋巴瘤#

4篇内容 | 2687人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2253294, encodeId=108f225329445, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=d42712040800' target=_blank style='color:#2F92EE;'>#异基因CAR-T#</a>, objectTitle=【JCO】异基因CAR-T cema-cel治疗R/R LBCL的1期研究结果, objectType=article, longId=864421, objectId=1da586442141, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739952514024_8538692.jpg, objectUrl=/article/show_article.do?id=1da586442141, replyNumber=0, likeNumber=10, createdTime=2025-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1da586442141, moduleTitle=【JCO】异基因CAR-T cema-cel治疗R/R LBCL的1期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da586442141)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2252541, encodeId=d49f225254109, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a>高危大B细胞淋巴瘤（LBCL）使用标准一线免疫化疗的复发率很高，, objectTitle=【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果, objectType=article, longId=863622, objectId=ae9b863622b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736833480786_8538692.jpg, objectUrl=/article/show_article.do?id=ae9b863622b0, replyNumber=0, likeNumber=12, createdTime=2025-02-18, rootId=0, userName=ms4000001513304915, userId=a1646442901, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=广东省, moduleDTOList=[ModuleDTO(moduleId=ae9b863622b0, moduleTitle=【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae9b863622b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2252510, encodeId=d71c225251009, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> 高危大B细胞淋巴瘤（LBCL）使用标准一线免疫化疗的复发率很高，尤其是在具有高国际预后指数（IPI）评分（≥3）或双/三打击淋巴瘤的患者中。Axicabtagene ciloleucel（axi-cel）是一种自体CD19 CAR-T细胞疗法，在LBCL治疗中显示出潜力，尤其是在早期复发或难治性患者中。, objectTitle=大B细胞淋巴瘤, objectType=topic, longId=43555, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=9, createdTime=2025-02-18, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2252475, encodeId=bcc322524e5f3, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=16ee12435eb0' target=_blank style='color:#2F92EE;'>#ZUMA-12研究#</a>, objectTitle=【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果, objectType=article, longId=863622, objectId=ae9b863622b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250114/1736833480786_8538692.jpg, objectUrl=/article/show_article.do?id=ae9b863622b0, replyNumber=0, likeNumber=21, createdTime=2025-02-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=ae9b863622b0, moduleTitle=【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae9b863622b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2231021, encodeId=c1a422310212f, content=<a href='/topic/show?id=56b0194220e' target=_blank style='color:#2F92EE;'>#一线治疗#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a>, objectTitle=【Blood】Gilles Salles教授：大B细胞淋巴瘤一线临床试验的现状和问题, objectType=article, longId=846972, objectId=e9b68469e287, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719537907810_5579292.png, objectUrl=/article/show_article.do?id=e9b68469e287, replyNumber=0, likeNumber=48, createdTime=2024-10-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e9b68469e287, moduleTitle=【Blood】Gilles Salles教授：大B细胞淋巴瘤一线临床试验的现状和问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9b68469e287)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219590, encodeId=7ae22219590a5, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【JHO】预测CD19 CAR-T治疗LBCL后重度CRS和ICANS的新型评分系统, objectType=article, longId=838557, objectId=879b83855ed2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722566367436_8538692.jpg, objectUrl=/article/show_article.do?id=879b83855ed2, replyNumber=0, likeNumber=77, createdTime=2024-08-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=879b83855ed2, moduleTitle=【JHO】预测CD19 CAR-T治疗LBCL后重度CRS和ICANS的新型评分系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=879b83855ed2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216459, encodeId=20e7221645980, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a> <a href='/topic/show?id=c0ad429356' target=_blank style='color:#2F92EE;'>#CD22#</a>, objectTitle=柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？, objectType=article, longId=835565, objectId=bd9683556534, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240719/1721377067764_92910.png, objectUrl=/article/show_article.do?id=bd9683556534, replyNumber=0, likeNumber=84, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bd9683556534, moduleTitle=柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd9683556534)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2214233, encodeId=0dd222142333f, content=<a href='/topic/show?id=31978e07508' target=_blank style='color:#2F92EE;'>#苯达莫司汀#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=978a113610c8' target=_blank style='color:#2F92EE;'>#R/R LBCL#</a>, objectTitle=【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效, objectType=article, longId=833752, objectId=b9a0833e52e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240710/1720579036530_1608702.png, objectUrl=/article/show_article.do?id=b9a0833e52e2, replyNumber=0, likeNumber=111, createdTime=2024-07-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b9a0833e52e2, moduleTitle=【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a0833e52e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212777, encodeId=4ce12212e77ff, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=CAR-T治疗后进展LBCL患者的后续治疗及结局, objectType=article, longId=827854, objectId=a1cf82e85422, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719538044546_5579292.jpg, objectUrl=/article/show_article.do?id=a1cf82e85422, replyNumber=0, likeNumber=107, createdTime=2024-07-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a1cf82e85422, moduleTitle=CAR-T治疗后进展LBCL患者的后续治疗及结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1cf82e85422)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211800, encodeId=9d20221180010, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=8f6c254e71b' target=_blank style='color:#2F92EE;'>#代谢肿瘤体积#</a>, objectTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局, objectType=article, longId=831718, objectId=fbc6831e1860, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719325149652_5579292.png, objectUrl=/article/show_article.do?id=fbc6831e1860, replyNumber=0, likeNumber=113, createdTime=2024-06-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fbc6831e1860, moduleTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbc6831e1860)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2210091, encodeId=ad4f2210091d9, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效, objectType=article, longId=830220, objectId=ff5a830220a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240615/1718464643656_92910.jpg, objectUrl=/article/show_article.do?id=ff5a830220a4, replyNumber=0, likeNumber=82, createdTime=2024-06-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ff5a830220a4, moduleTitle=【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff5a830220a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208666, encodeId=9609220866618, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局, objectType=article, longId=829004, objectId=8f4482900415, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240606/1717660439509_5579292.jpg, objectUrl=/article/show_article.do?id=8f4482900415, replyNumber=0, likeNumber=0, createdTime=2024-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8f4482900415, moduleTitle=【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f4482900415)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208486, encodeId=2d1422084869e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验, objectType=article, longId=828894, objectId=c4d7828894bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717570813056_5579292.jpg, objectUrl=/article/show_article.do?id=c4d7828894bf, replyNumber=0, likeNumber=91, createdTime=2024-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c4d7828894bf, moduleTitle=【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4d7828894bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207870, encodeId=9fe0220e87032, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=68d6115128e1' target=_blank style='color:#2F92EE;'>#格菲妥单抗#</a>, objectTitle=【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型, objectType=article, longId=828343, objectId=651d82834325, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240601/1717250825584_5579292.jpg, objectUrl=/article/show_article.do?id=651d82834325, replyNumber=0, likeNumber=135, createdTime=2024-06-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=651d82834325, moduleTitle=【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=651d82834325)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205822, encodeId=6e3122058222d, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析, objectType=article, longId=826858, objectId=973982685879, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716265568710_5579292.jpg, objectUrl=/article/show_article.do?id=973982685879, replyNumber=0, likeNumber=117, createdTime=2024-05-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=973982685879, moduleTitle=Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973982685879)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204281, encodeId=03fc2204281dd, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念, objectType=article, longId=825529, objectId=45f482552988, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240512/1715509447146_5579292.jpg, objectUrl=/article/show_article.do?id=45f482552988, replyNumber=0, likeNumber=146, createdTime=2024-05-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=45f482552988, moduleTitle=【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45f482552988)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203887, encodeId=fe31220388e95, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=b2f61143192e' target=_blank style='color:#2F92EE;'>#免疫豁免#</a>, objectTitle=blood综述：免疫豁免部位的原发性大B细胞淋巴瘤, objectType=article, longId=825049, objectId=b7a8825049cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240510/1715318194666_92910.png, objectUrl=/article/show_article.do?id=b7a8825049cb, replyNumber=0, likeNumber=136, createdTime=2024-05-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b7a8825049cb, moduleTitle=blood综述：免疫豁免部位的原发性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7a8825049cb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203756, encodeId=06902203e56ca, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=8f6c254e71b' target=_blank style='color:#2F92EE;'>#代谢肿瘤体积#</a> <a href='/topic/show?id=a80f10e3046' target=_blank style='color:#2F92EE;'>#LBCL#</a>, objectTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局, objectType=article, longId=825081, objectId=03a3825081b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=03a3825081b6, replyNumber=0, likeNumber=130, createdTime=2024-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=03a3825081b6, moduleTitle=【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03a3825081b6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200417, encodeId=d13c220041e42, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=031811380ed4' target=_blank style='color:#2F92EE;'>#伴IRF4重排#</a>, objectTitle=【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？, objectType=article, longId=822301, objectId=a408822301ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=a408822301ae, replyNumber=0, likeNumber=108, createdTime=2024-04-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a408822301ae, moduleTitle=【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a408822301ae)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195720, encodeId=53522195e20fb, content=<a href='/topic/show?id=247743555b6' target=_blank style='color:#2F92EE;'>#大B细胞淋巴瘤#</a> <a href='/topic/show?id=142f5429388' target=_blank style='color:#2F92EE;'>#扁桃体#</a> <a href='/topic/show?id=71a91128139f' target=_blank style='color:#2F92EE;'>#IRF4重排#</a>, objectTitle=病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例, objectType=article, longId=816647, objectId=17d981664e8f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=17d981664e8f, replyNumber=0, likeNumber=92, createdTime=2024-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=17d981664e8f, moduleTitle=病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17d981664e8f)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

大B细胞淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #异基因CAR-T#

【JCO】异基因CAR-T cema-cel治疗R/R LBCL的1期研究结果

2025-02-24发表于陕西省

ms4000001513304915 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤#高危大B细胞淋巴瘤（LBCL）使用标准一线免疫化疗的复发率很高，

【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果

2025-02-18发表于广东省

yangchou (审核中...)

前往app查看评论内容

全文收起 #大B细胞淋巴瘤# 高危大B细胞淋巴瘤（LBCL）使用标准一线免疫化疗的复发率很高，尤其是在具有高国际预后指数（IPI）评分（≥3）或双/三打击淋巴瘤的患者中。Axicabtagene ciloleucel（axi-cel）是一种自体CD19 CAR-T细胞疗法，在LBCL治疗中显示出潜力，尤其是在早期复发或难治性患者中。

2025-02-18发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #ZUMA-12研究#

【Blood】axi-cel一线治疗高危大B细胞淋巴瘤的ZUMA-12研究四年随访结果

2025-02-18发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#一线治疗# #大B细胞淋巴瘤#

【Blood】Gilles Salles教授：大B细胞淋巴瘤一线临床试验的现状和问题

2024-10-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T# #LBCL#

【JHO】预测CD19 CAR-T治疗LBCL后重度CRS和ICANS的新型评分系统

2024-08-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T细胞治疗# #CD22#

柳叶刀发表CD22 CAR-T治疗CAR19失败的LBCL的I期研究，新的希望即将来临？

2024-07-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#苯达莫司汀# #大B细胞淋巴瘤# #R/R LBCL#

【Hemasphere】苯达莫司汀作为R/R LBCL CAR-T桥接治疗安全有效

2024-07-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T# #LBCL#

CAR-T治疗后进展LBCL患者的后续治疗及结局

2024-07-02发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #代谢肿瘤体积#

【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积可预测结局

2024-06-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T#

【AJH】CD19 CAR-T治疗226例高龄RR LBCL患者安全有效

2024-06-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T#

【Hemasphere】387例LBCL患者CAR-T治疗进展后的治疗及结局

2024-06-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#二线治疗# #大B细胞淋巴瘤# #LBCL#

【BJH】axi-cel二线治疗早期复发或原发难治LBCL的真实世界经验

2024-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #格菲妥单抗#

【Blood Adv】格菲妥单抗治疗DLBCL中≥2级CRS的预测模型

2024-06-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #CAR-T# #LBCL#

Leukemia：完全缓解的LBCL患者接受CAR-T细胞治疗：一项CIBMTR分析

2024-05-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #LBCL#

【Blood Adv】前瞻性研究明确定义原发难治性大B细胞淋巴瘤的概念

2024-05-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#DLBCL# #大B细胞淋巴瘤# #免疫豁免#

blood综述：免疫豁免部位的原发性大B细胞淋巴瘤

2024-05-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #代谢肿瘤体积# #LBCL#

【Blood】ZUMA-7研究探索性分析，代谢肿瘤体积影响患者结局

2024-05-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #伴IRF4重排#

【衡道丨病例】一文详解！伴IRF4重排的大B细胞淋巴瘤如何诊断？

2024-04-25发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#大B细胞淋巴瘤# #扁桃体# #IRF4重排#

病例分享 | 扁桃体伴IRF4重排的大B细胞淋巴瘤一例

2024-03-27发表于陕西省

科室
- - 订阅+
  - 更多科室
工具
服务